NEKTAR THERAPEUTICS (NKTR) Fundamental Analysis & Valuation

NASDAQ:NKTR • US6402683063

Current stock price

72.08 USD
-0.88 (-1.21%)
At close:
72.08 USD
0 (0%)
After Hours:

This NKTR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NKTR Profitability Analysis

1.1 Basic Checks

  • NKTR had negative earnings in the past year.
  • NKTR had a negative operating cash flow in the past year.
  • NKTR had negative earnings in each of the past 5 years.
  • In the past 5 years NKTR always reported negative operating cash flow.
NKTR Yearly Net Income VS EBIT VS OCF VS FCFNKTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M

1.2 Ratios

  • NKTR has a worse Return On Assets (-58.51%) than 65.80% of its industry peers.
  • NKTR's Return On Equity of -182.65% is on the low side compared to the rest of the industry. NKTR is outperformed by 72.02% of its industry peers.
Industry RankSector Rank
ROA -58.51%
ROE -182.65%
ROIC N/A
ROA(3y)-55.67%
ROA(5y)-53.14%
ROE(3y)-196.42%
ROE(5y)-153.36%
ROIC(3y)N/A
ROIC(5y)N/A
NKTR Yearly ROA, ROE, ROICNKTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • NKTR has a Gross Margin of 100.00%. This is amongst the best in the industry. NKTR outperforms 97.93% of its industry peers.
  • NKTR's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NKTR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5Y2.77%
NKTR Yearly Profit, Operating, Gross MarginsNKTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NKTR Health Analysis

2.1 Basic Checks

  • NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NKTR has more shares outstanding
  • The number of shares outstanding for NKTR has been increased compared to 5 years ago.
  • Compared to 1 year ago, NKTR has an improved debt to assets ratio.
NKTR Yearly Shares OutstandingNKTR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
NKTR Yearly Total Debt VS Total AssetsNKTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • NKTR has an Altman-Z score of -12.62. This is a bad value and indicates that NKTR is not financially healthy and even has some risk of bankruptcy.
  • NKTR has a worse Altman-Z score (-12.62) than 75.13% of its industry peers.
  • A Debt/Equity ratio of 0.70 indicates that NKTR is somewhat dependend on debt financing.
  • NKTR's Debt to Equity ratio of 0.70 is on the low side compared to the rest of the industry. NKTR is outperformed by 66.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF N/A
Altman-Z -12.62
ROIC/WACCN/A
WACC9.46%
NKTR Yearly LT Debt VS Equity VS FCFNKTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • NKTR has a Current Ratio of 4.97. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.97, NKTR is in the better half of the industry, outperforming 65.80% of the companies in the same industry.
  • A Quick Ratio of 4.97 indicates that NKTR has no problem at all paying its short term obligations.
  • NKTR's Quick ratio of 4.97 is fine compared to the rest of the industry. NKTR outperforms 67.36% of its industry peers.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.97
NKTR Yearly Current Assets VS Current LiabilitesNKTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. NKTR Growth Analysis

3.1 Past

  • NKTR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.82%, which is quite good.
  • Looking at the last year, NKTR shows a very negative growth in Revenue. The Revenue has decreased by -43.89% in the last year.
  • NKTR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.43% yearly.
EPS 1Y (TTM)12.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.83%
Revenue 1Y (TTM)-43.89%
Revenue growth 3Y-15.67%
Revenue growth 5Y-18.43%
Sales Q2Q%-25.25%

3.2 Future

  • The Earnings Per Share is expected to decrease by -0.64% on average over the next years.
  • NKTR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.10% yearly.
EPS Next Y3.78%
EPS Next 2Y-8.64%
EPS Next 3Y-8.8%
EPS Next 5Y-0.64%
Revenue Next Year-6.31%
Revenue Next 2Y-10.59%
Revenue Next 3Y2.46%
Revenue Next 5Y46.1%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NKTR Yearly Revenue VS EstimatesNKTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
NKTR Yearly EPS VS EstimatesNKTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 20 -20 40 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. NKTR Valuation Analysis

4.1 Price/Earnings Ratio

  • NKTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NKTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTR Price Earnings VS Forward Price EarningsNKTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTR Per share dataNKTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • NKTR's earnings are expected to decrease with -8.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.64%
EPS Next 3Y-8.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NKTR Dividend Analysis

5.1 Amount

  • NKTR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NKTR Fundamentals: All Metrics, Ratios and Statistics

NEKTAR THERAPEUTICS

NASDAQ:NKTR (3/25/2026, 5:50:53 PM)

After market: 72.08 0 (0%)

72.08

-0.88 (-1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-06
Inst Owners64.42%
Inst Owner Change18.19%
Ins Owners0.61%
Ins Owner Change1.24%
Market Cap2.07B
Revenue(TTM)55.23M
Net Income(TTM)-164.08M
Analysts85.71
Price Target132.45 (83.75%)
Short Float %12.32%
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.59%
Min EPS beat(2)29.47%
Max EPS beat(2)31.71%
EPS beat(4)3
Avg EPS beat(4)5.67%
Min EPS beat(4)-43.22%
Max EPS beat(4)31.71%
EPS beat(8)6
Avg EPS beat(8)3.41%
EPS beat(12)7
Avg EPS beat(12)-0.81%
EPS beat(16)11
Avg EPS beat(16)5.84%
Revenue beat(2)2
Avg Revenue beat(2)60.26%
Min Revenue beat(2)15.04%
Max Revenue beat(2)105.49%
Revenue beat(4)3
Avg Revenue beat(4)22.05%
Min Revenue beat(4)-33.31%
Max Revenue beat(4)105.49%
Revenue beat(8)6
Avg Revenue beat(8)22.86%
Revenue beat(12)9
Avg Revenue beat(12)18.54%
Revenue beat(16)10
Avg Revenue beat(16)13.46%
PT rev (1m)13.48%
PT rev (3m)13.48%
EPS NQ rev (1m)8.86%
EPS NQ rev (3m)8.86%
EPS NY rev (1m)2.51%
EPS NY rev (3m)1.46%
Revenue NQ rev (1m)-8.67%
Revenue NQ rev (3m)-8.72%
Revenue NY rev (1m)-1.98%
Revenue NY rev (3m)-1.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.44
P/FCF N/A
P/OCF N/A
P/B 23.02
P/tB 23.02
EV/EBITDA N/A
EPS(TTM)-10.2
EYN/A
EPS(NY)-9.81
Fwd EYN/A
FCF(TTM)-7.3
FCFYN/A
OCF(TTM)-7.27
OCFYN/A
SpS1.93
BVpS3.13
TBVpS3.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.51%
ROE -182.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-55.67%
ROA(5y)-53.14%
ROE(3y)-196.42%
ROE(5y)-153.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5Y2.77%
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.6%
Cap/Sales 1.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.97
Quick Ratio 4.97
Altman-Z -12.62
F-Score3
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)43.03%
Cap/Depr(5y)55.87%
Cap/Sales(3y)1.34%
Cap/Sales(5y)4.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.83%
EPS Next Y3.78%
EPS Next 2Y-8.64%
EPS Next 3Y-8.8%
EPS Next 5Y-0.64%
Revenue 1Y (TTM)-43.89%
Revenue growth 3Y-15.67%
Revenue growth 5Y-18.43%
Sales Q2Q%-25.25%
Revenue Next Year-6.31%
Revenue Next 2Y-10.59%
Revenue Next 3Y2.46%
Revenue Next 5Y46.1%
EBIT growth 1Y-0.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.67%
OCF growth 3YN/A
OCF growth 5YN/A

NEKTAR THERAPEUTICS / NKTR Fundamental Analysis FAQ

What is the fundamental rating for NKTR stock?

ChartMill assigns a fundamental rating of 2 / 10 to NKTR.


What is the valuation status for NKTR stock?

ChartMill assigns a valuation rating of 0 / 10 to NEKTAR THERAPEUTICS (NKTR). This can be considered as Overvalued.


Can you provide the profitability details for NEKTAR THERAPEUTICS?

NEKTAR THERAPEUTICS (NKTR) has a profitability rating of 1 / 10.